2.46
+0.13(+5.58%)
Currency In USD
| Previous Close | 2.33 |
| Open | 2.36 |
| Day High | 2.48 |
| Day Low | 2.36 |
| 52-Week High | 13.52 |
| 52-Week Low | 2.02 |
| Volume | 166,200 |
| Average Volume | 3.01M |
| Market Cap | 12.85M |
| PE | -0.25 |
| EPS | -10.01 |
| Moving Average 50 Days | 2.6 |
| Moving Average 200 Days | 4.87 |
| Change | 0.13 |
If you invested $1000 in Beyond Air, Inc. (XAIR) since IPO date, it would be worth $41.69 as of September 29, 2025 at a share price of $2.46. Whereas If you bought $1000 worth of Beyond Air, Inc. (XAIR) shares 5 years ago, it would be worth $23.52 as of September 29, 2025 at a share price of $2.46.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Beyond Air to Participate in the ROTH 4th Annual Healthcare Opportunities Conference
GlobeNewswire Inc.
Sep 22, 2025 12:00 PM GMT
GARDEN CITY, N.Y., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve t
Beyond Air Announces Exercise of Warrants for $3.25 Million of Gross Proceeds
GlobeNewswire Inc.
Sep 08, 2025 7:55 PM GMT
GARDEN CITY, N.Y., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve t
NeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Most Common and Deadliest Primary Malignant Brain Cancer in Adults
GlobeNewswire Inc.
Sep 08, 2025 12:00 PM GMT
BOSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical company focused on developing treatments for neurological disorders and neuro-oncology, and a subsidiary of Beyond Air (NASDAQ: XAIR), today announced that the U.S. Food and D